Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2004

01-09-2004 | Original Article

Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3

Authors: P. Mahy, M. De Bast, P. H. Leveque, J. Gillart, D. Labar, J. Marchand, V. Gregoire

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2004

Login to get access

Abstract

The 2-nitroimidazole derivative 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)acetamide (EF3) is a marker which forms adducts into hypoxic cells. Radiosynthesis of [18F]EF3 was recently performed by our group. Our aim was to study the pharmacokinetics, biodistribution, metabolism and specificity for hypoxia of [18F]EF3. MCa-4, SCC VII, NFSA, FSA, FSA II or Sa-NH tumour-bearing C3H mice were injected intravenously with [18F]EF3 and allowed to breathe air, 10% O2 or carbogen until sacrifice 5–770 min after injection. Radioactivity was measured ex vivo in various organs, including urine and faeces. Selected organs were additionally processed to measure tracer metabolites with high-performance liquid chromatography. The half-life in blood was 73.9 min. [18F]EF3 was eliminated mainly via the kidneys, with 75% of the injected activity found in the urine by 12 h 50 min. The biodistribution was fast and homogeneous except in the brain and the bone, where it was significantly lower, and in the liver and the kidney, where it was significantly higher. In most organs, the exceptions being the gastrointestinal and urinary tract, tissue-to-blood ratios were below or close to unity. In tumours, a relative accumulation of the tracer was observed with time, which, at 220 min after injection, depended on tumour strain and oxygenation conditions, i.e. 10% O2 significantly increased the tumour-to-muscle ratio whereas carbogen decreased it. [18F]EF3 was rapidly metabolised in the kidney and the liver. [18F]EF3 is a promising tracer for detection of tumour hypoxia. A phase I study in head and neck cancer patients is in progress at our institution.
Literature
1.
Horsman MR, Nordsmark M, Overgaard J. Techniques to assess the oxygenation of human tumors. State of the art. Strahlenther Onkol 1998;174(Suppl 4):2–5
2.
Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997;37:897–905PubMed
3.
Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687–702PubMed
4.
Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazole-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]. Cancer Res 2000;60:2636–2642PubMed
5.
Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3–31PubMed
6.
Raleigh JA, Koch CJ. The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol 1990;40:2457–2464PubMed
7.
Kaanders JHAM, Wijffels KIEM, Marres HAM, Pop LAM, Marres HAM, Ljungkvist ASE, Pop LAM, van den Hoogen FJA, de Wilde PCM, Bussink J, Raleigh JA, van der Kogel AJ. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066–7074PubMed
8.
Evans SM, Judy KD, Dunphy I, Nelson P, Magarelli D, Jenkins WT, Hahn SM, Collins RM, Koch CJ. Hypoxia, as measured by EF5 binding, predicts recurrence in adult brain tumors. Int J Radiat Oncol Biol Phys 2003;55:470
9.
Tubis M, Krishnamurthy G, Endow JS, Stein RA, Suwanik R, Blahd WH. Labeled metronidazole as potential agents for amebic abscess imaging. J Nucl Med 1975;14:163–171
10.
Chapman JD, Franko AJ, Koch CJ. The fraction of hypoxic clonogenic cells in tumor populations. In: Nervi C, Arcangeli G, Mauro F, eds. Proceedings of the Second Rome International Symposium (1980): biological bases and clinical implications of tumor radioresistance. New York: Masson; 1983:61–73
11.
Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321–329PubMed
12.
Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292–304PubMed
13.
Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985–991PubMed
14.
Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84–92PubMed
15.
Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199–212PubMed
16.
Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133–2137PubMed
17.
Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391–398PubMed
18.
Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417–428PubMed
19.
Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, Yu TW, Chou KL, Chen KY. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996;23:1378–1383PubMed
20.
Shelton ME, Dence CS, Hwang DR, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16:477–485PubMed
21.
Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, Egan GF, Scott AM, Bladin CF, McKay WJ, Donnan GA. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology 1998;51:1617–1621PubMed
22.
Liu RS, Chu LS, Yen SH, Chang CP, Chou KL, Wu LC, Chang CW, Lui MT, Chen KY, Yeh SH. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 1996;23:1384–1387PubMed
23.
Tewson TJ. Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol 1997;24:755–760CrossRefPubMed
24.
Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795–800PubMed
25.
Lehtio K, Oikonen V, Gronroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grenman R, Nuutila P, Minn H. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [15O]H2O and [18F]fluoroerythronitroimidazole PET. J Nucl Med 2001;42:1643–1652
26.
Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, Minn H. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003;30:101–108
27.
Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998;8:143–150PubMed
28.
Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier WR Jr, Koch CJ. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259–266PubMed
29.
Evans SM, Kachur AV, Shiue CA, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR Jr, Koch CJ. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327–336PubMed
30.
Josse O, Labar D, Georges B, Gregoire V, Marchand J. Synthesis of [18F]-labelled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001;9:665–675CrossRefPubMed
31.
Milas L, Hunter N, Mason K, Withers HR. Immunological resistance to pulmonary metastases in C3Hf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 1974;34:61–71PubMed
32.
Mahy P, De Bast M, Gallez B, Gueulette J, Koch CJ, Scalliet P, Grégoire V. In vivo colocalisation of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol 2003;67:53–61CrossRefPubMed
33.
Gronroos T, Eskola O, Lehtio K, Minn H, Marjamaki P, Bergman J, Haaparanta M, Forsback S, Solin O. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001;42:1397–1404
34.
Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56:405–411PubMed
35.
Cobb LM, Nolan J, Butler SA. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. Br J Cancer 1990;62:915–918PubMed
36.
Laughlin KM, Evans SM, Jenkins WT, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996;277:1049–1057
37.
Phillips TL, Ross G. Time-dose relationships in the mouse esophagus. Radiology 1974;113:435–440PubMed
38.
Cobb LM, Nolan J, Butler S. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Biol Phys 1990;18:347–351PubMed
39.
Cobb LM, Nolan J, Hacker T. Retention of misonidazole in normal and malignant tissues: interplay of hypoxia and reductases. Int J Radiat Oncol Biol Phys 1992;22:655–659PubMed
40.
Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrom H, Bergh J, Antoni G, Langstrom B, Bergstrom M. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998;27:72–76CrossRefPubMed
41.
Milross CG, Peters LJ, Hunter NR, Mason KA, Tucker SL, Milas L. Polarographic pO2 measurement in mice: effect of tumor site, site of implantation, and anesthesia. Rad Oncol Invest 1996;7:108–114CrossRef
42.
Mahy P, Gueulette J, Scalliet P, Grégoire V. Quantitative detection of EF5 adducts with immunofluorescence (IF) and flow cytometry (FC) to measure hypoxia in murine tumors. Cancer Res 1999;40:641
43.
Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–237CrossRefPubMed
44.
Zanzonico P, O’Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117–128CrossRefPubMed
45.
Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072–1079PubMed
46.
Graham MM, Peterson LM, Link JM, Evans ML, Rasey JS, Koh WJ, Caldwell JH, Krohn KA. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997;38:1631–1636PubMed
47.
Koch CJ, Hahn SM, Rockwell Jr K, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol 2001;48:177–187CrossRefPubMed
Metadata
Title
Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3
Authors
P. Mahy
M. De Bast
P. H. Leveque
J. Gillart
D. Labar
J. Marchand
V. Gregoire
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1573-2

Other articles of this Issue 9/2004

European Journal of Nuclear Medicine and Molecular Imaging 9/2004 Go to the issue

Original Article

The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules

Original Article

A catheter-based radiation detector for endovascular detection of atheromatous plaques

Editorial

Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?

Molecular Imaging

Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy

Image of the Month

Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion

News & Views

September 2004